SkinBioTherapeutics Plc
SBTX.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | – | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | – | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 283.6% | 815.5% | 76.6% | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 58.3% | 56.5% | 64.5% | 60.6% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -4.2% | -225.1% | -2,237.8% | -3,949.1% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -15% | -237.9% | -2,146.9% | -3,735.4% |
| EPS Diluted | -0.003 | -0.015 | -0.017 | -0.018 |
| % Growth | 79.9% | 10.5% | 3.4% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |